{"entity": "journal", "iuid": "0a06646a775f4d5095246f93b26dc957", "timestamp": "2026-09-05T17:51:55.522Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/journal/Theranostics.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/journal/Theranostics"}}, "title": "Theranostics", "issn": "1838-7640", "issn-l": "1838-7640", "publications_count": 3, "publications": [{"entity": "publication", "iuid": "ca81a9565a8640e4a04071ce00685053", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/ca81a9565a8640e4a04071ce00685053.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/ca81a9565a8640e4a04071ce00685053"}}, "title": "Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics.", "authors": [{"family": "Velikyan", "given": "Irina", "initials": "I"}, {"family": "Eriksson", "given": "Olof", "initials": "O"}], "type": "journal article", "published": "2020-01-01", "journal": {"title": "Theranostics", "issn": "1838-7640", "issn-l": "1838-7640", "volume": "10", "issue": "1", "pages": "437-461"}, "abstract": "In the light of theranostics/radiotheranostics and prospective of personalized medicine in diabetes and oncology, this review presents prior and current advances in the development of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like peptide-1 receptor. The review covers chemistry, preclinical, and clinical evaluation. Such critical aspects as structure-activity-relationship, stability, physiological potency, kidney uptake, and dosimetry are discussed.", "doi": "10.7150/thno.38366", "pmid": "31903131", "labels": {"Olof Eriksson": null, "SciLifeLab Fellow": null}, "xrefs": [{"db": "pmc", "key": "PMC6929622"}, {"db": "pii", "key": "thnov10p0437"}], "notes": [], "created": "2020-10-06T13:34:36.165Z", "modified": "2023-05-14T14:54:13.471Z"}, {"entity": "publication", "iuid": "baafe6b78297457e83c3e95f4543e578", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/baafe6b78297457e83c3e95f4543e578.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/baafe6b78297457e83c3e95f4543e578"}}, "title": "Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model.", "authors": [{"family": "Mitran", "given": "Bogdan", "initials": "B"}, {"family": "G\u00fcler", "given": "Rezan", "initials": "R"}, {"family": "Roche", "given": "Francis P", "initials": "FP"}, {"family": "Lindstr\u00f6m", "given": "Elin", "initials": "E"}, {"family": "Selvaraju", "given": "Ram Kumar", "initials": "RK"}, {"family": "Fleetwood", "given": "Filippa", "initials": "F"}, {"family": "Rinne", "given": "Sara S", "initials": "SS"}, {"family": "Claesson-Welsh", "given": "Lena", "initials": "L"}, {"family": "Tolmachev", "given": "Vladimir", "initials": "V"}, {"family": "St\u00e5hl", "given": "Stefan", "initials": "S"}, {"family": "Orlova", "given": "Anna", "initials": "A"}, {"family": "L\u00f6fblom", "given": "John", "initials": "J"}], "type": "journal article", "published": "2018-08-07", "journal": {"title": "Theranostics", "issn": "1838-7640", "volume": "8", "issue": "16", "pages": "4462-4476", "issn-l": "1838-7640"}, "abstract": "Vascular endothelial growth factor receptor-2 (VEGFR2) is a key mediator of angiogenesis and therefore a promising therapeutic target in malignancies including glioblastoma multiforme (GBM). Molecular imaging of VEGFR2 expression may enable patient stratification for antiangiogenic therapy. The goal of the current study was to evaluate the capacity of the novel anti-VEGFR2 biparatopic affibody conjugate (ZVEGFR2-Bp2) for in vivo visualization of VEGFR2 expression in GBM. Methods: ZVEGFR2-Bp2 coupled to a NODAGA chelator was generated and radiolabeled with indium-111. The VEGFR2-expressing murine endothelial cell line MS1 was used to evaluate in vitro binding specificity and affinity, cellular processing and targeting specificity in mice. Further tumor targeting was studied in vivo in GL261 glioblastoma orthotopic tumors. Experimental imaging was performed. Results: [111In]In-NODAGA-ZVEGFR2-Bp2 bound specifically to VEGFR2 (KD=33\u00b118 pM). VEGFR2-mediated accumulation was observed in liver, spleen and lungs. The tumor-to-organ ratios 2 h post injection for mice bearing MS1 tumors were approximately 11 for blood, 15 for muscles and 78 for brain. Intracranial GL261 glioblastoma was visualized using SPECT/CT. The activity uptake in tumors was significantly higher than in normal brain tissue. The tumor-to-cerebellum ratios after injection of 4 \u00b5g [111In]In-NODAGA-ZVEGFR2-Bp2 were significantly higher than the ratios observed for the 40 \u00b5g injected dose and for the non-VEGFR2 binding size-matched conjugate, demonstrating target specificity. Microautoradiography of cryosectioned CNS tissue was in good agreement with the SPECT/CT images. Conclusion: The anti-VEGFR2 affibody conjugate [111In]In-NODAGA-ZVEGFR2-Bp2 specifically targeted VEGFR2 in vivo and visualized its expression in a murine GBM orthotopic model. Tumor-to-blood ratios for [111In]In-NODAGA-ZVEGFR2-Bp2 were higher compared to other VEGFR2 imaging probes. [111In]In-NODAGA-ZVEGFR2-Bp2 appears to be a promising probe for in vivo noninvasive visualization of tumor angiogenesis in glioblastoma.", "doi": "10.7150/thno.24395", "pmid": "30214632", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6134937"}, {"db": "pii", "key": "thnov08p4462"}], "notes": [], "created": "2026-08-21T13:07:19.324Z", "modified": "2026-08-21T13:07:19.356Z"}, {"entity": "publication", "iuid": "1f1447a762d14ea5a7806d735a5866e6", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/1f1447a762d14ea5a7806d735a5866e6.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/1f1447a762d14ea5a7806d735a5866e6"}}, "title": "Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes.", "authors": [{"family": "Puhka", "given": "Maija", "initials": "M"}, {"family": "Takatalo", "given": "Maarit", "initials": "M"}, {"family": "Nordberg", "given": "Maria-Elisa", "initials": "ME"}, {"family": "Valkonen", "given": "Sami", "initials": "S"}, {"family": "Nandania", "given": "Jatin", "initials": "J"}, {"family": "Aatonen", "given": "Maria", "initials": "M"}, {"family": "Yliperttula", "given": "Marjo", "initials": "M"}, {"family": "Laitinen", "given": "Saara", "initials": "S"}, {"family": "Velagapudi", "given": "Vidya", "initials": "V"}, {"family": "Mirtti", "given": "Tuomas", "initials": "T"}, {"family": "Kallioniemi", "given": "Olli", "initials": "O"}, {"family": "Rannikko", "given": "Antti", "initials": "A"}, {"family": "Siljander", "given": "Pia R-M", "initials": "PR"}, {"family": "Af H\u00e4llstr\u00f6m", "given": "Taija Maria", "initials": "TM"}], "type": "journal article", "published": "2017-08-23", "journal": {"title": "Theranostics", "issn": "1838-7640", "volume": "7", "issue": "16", "pages": "3824-3841", "issn-l": "1838-7640"}, "abstract": "Body fluids are a rich source of extracellular vesicles (EVs), which carry cargo derived from the secreting cells. So far, biomarkers for pathological conditions have been mainly searched from their protein, (mi)RNA, DNA and lipid cargo. Here, we explored the small molecule metabolites from urinary and platelet EVs relative to their matched source samples. As a proof-of-concept study of intra-EV metabolites, we compared alternative normalization methods to profile urinary EVs from prostate cancer patients before and after prostatectomy and from healthy controls.\n\nWe employed targeted ultra-performance liquid chromatography-tandem mass spectrometry to profile over 100 metabolites in the isolated EVs, original urine samples and platelets. We determined the enrichment of the metabolites in the EVs and analyzed their subcellular origin, pathways and relevant enzymes or transporters through data base searches. EV- and urine-derived factors and ratios between metabolites were tested for normalization of the metabolomics data.\n\nApproximately 1 x 10\n\nOur results suggest that metabolite analysis of EVs from different samples is feasible using a high-throughput platform and relatively small amount of sample material. With the knowledge about the specific enrichment of metabolites and normalization methods, EV metabolomics could be used to gain novel biomarker data not revealed by the analysis of the original EV source materials.", "doi": "10.7150/thno.19890", "pmid": "29109780", "labels": {"Affiliated researcher": null}, "xrefs": [{"db": "pii", "key": "thnov07p3824"}, {"db": "pmc", "key": "PMC5667407"}], "notes": [], "created": "2018-12-05T11:25:26.685Z", "modified": "2018-12-05T11:25:26.716Z"}], "created": "2018-12-05T11:25:26.698Z", "modified": "2020-11-27T13:12:57.204Z"}